ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apatinib

Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 13, 201247 company-led studies, 8 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicineits history only344 open or runningphase 3since Jan 13, 2012Aug 30, 2010none ahead
Elevar Therapeuticsits history only70 open or runningphase 3since Jan 24, 2017Dec 18, 2011none ahead
Bukwang Pharmaceuticalits history only10 open or runningphase 1since Feb 26, 2016Feb 26, 2016none ahead
GrandPharma (China)its history only11 open or runningphase 2since Aug 13, 2025Aug 13, 2025Dec 30, 2027phase 2 · NCT07334483
Guangzhou Virotech Pharmaceuticalits history only11 open or runningphase 3since May 8, 2026May 8, 2026Dec 31, 2028phase 3 · NCT07589244
Hansoh Pharmaceutical Groupits history only11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
HRYZ Biotechits history only11 open or runningearly phase 1since Aug 26, 2019Aug 26, 2019none ahead
Qilu Pharmaceutical10 open or runningphase 2since Aug 14, 2017Aug 14, 2017none ahead

Also a collaborator on its studies: Bukwang Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03267654 · 100 enrolled · China

TargetBeta

KDR →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

The one study Qilu Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03267654Carcinoma, Non-Small-Cell Lung · China2UNKNOWNOct 20, 2020100

How it is read

Names in the registry

  • “Apatinib”, 13 entries
  • “Rivoceranib”, 5 entries
  • “Apatinib Mesylate”, 5 entries
  • “apatinib”, 3 entries
  • “Fluzoparib+Apatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.